Skip to Main Content

Author Details

Jonathan Cebon
Australia Olivia Newton-John Cancer Research Institute, La Trobe University
1985
249
68
PMIDPaper TitleJournal TitlePublished Year
36692958Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?Cancer2023
37827066Durable response to combination immunotherapy using nivolumab and ipilimumab in metastatic succinate dehydrogenase (SDH)-deficient gastrointestinal stroma tumour.Eur J Cancer2023
34952480Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.Eur J Cancer2022
32740978Migratory cues controlling B-lymphocyte trafficking in human lymph nodes.Immunol Cell Biol2021
33918976Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses.Cancers (Basel)2021
33889439Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538.Oncoimmunology2021
33930312Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy.Cancer Cell2021
34782426Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.J Immunother Cancer2021
34131107Correction: BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.Cell Death Discov2021
34099918Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma.Nat Immunol2021
34210681Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.Clin Cancer Res2021
34177913<i>PDCD1</i> Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.Front Immunol2021
34050131A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma.Cell Death Discov2021
31580843A Distinct Pretreatment Immune Gene Signature in Lentigo Maligna Is Associated with Imiquimod Response.J Invest Dermatol2020
31919129Butyrophilin 2A1 is essential for phosphoantigen reactivity by γδ T cells.Science2020
33298868BCL-XL is an actionable target for treatment of malignant pleural mesothelioma.Cell Death Discov2020
32605909Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B.Clin Cancer Res2020
32938616Spliced Peptides and Cytokine-Driven Changes in the Immunopeptidome of Melanoma.Cancer Immunol Res2020
32737142Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141<sup>+</sup> dendritic cells to activate naïve and memory NY-ESO-1-specific CD8<sup>+</sup> T cells.J Immunother Cancer2020
32729929Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.JAMA Oncol2020
32894101Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.BMC Nephrol2020
32133394Tracking extracellular vesicle phenotypic changes enables treatment monitoring in melanoma.Sci Adv2020
32532787Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.Clin Cancer Res2020
32317292Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma.J Immunother Cancer2020
30549256Association of good oncological response to therapy with the development of rheumatic immune-related adverse events following PD-1 inhibitor therapy.Int J Rheum Dis2019
32721131A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastases.Cancer Rep (Hoboken)2019
31488221Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature.J Immunother Cancer2019
31095039Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.Melanoma Res2019
30731208Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.J Mol Diagn2019
30426665Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.Asia Pac J Clin Oncol2019
28991513Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib.J Clin Oncol2018
30096300Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.Cell2018
30042403Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.Sci Rep2018
30196539Neutrophil to lymphocyte ratio is an independent predictor of outcome for patients undergoing definitive resection for stage IV melanoma.J Surg Oncol2018
30348802Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules.Proc Natl Acad Sci U S A2018
30446791Perspective: cancer vaccines in the era of immune checkpoint blockade.Mamm Genome2018
30439628Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.Eur J Cancer2018
29552014Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional <i>Bacillus Calmette-Guérin</i> followed by Ipilimumab in Patients with Advanced Metastatic Melanoma.Front Immunol2018
29666298Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy.Oncologist2018
29662054Characterising the phenotypic evolution of circulating tumour cells during treatment.Nat Commun2018
29531227Divergent T-cell receptor recognition modes of a HLA-I restricted extended tumour-associated peptide.Nat Commun2018
28889792Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.N Engl J Med2017
28324885Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.Br J Cancer2017
28183192A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIXâ¿¢ adjuvant.Immunotherapy2017
28467829Whole-genome landscapes of major melanoma subtypes.Nature2017
28987768Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.Eur J Cancer2017
28963969Intercellular Resistance to BRAF Inhibition Can Be Mediated by Extracellular Vesicle-Associated PDGFRβ.Neoplasia2017
28886381Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.Cell2017
28813417CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.Nature2017
28729151Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial.Lancet Oncol2017
  • 1 - 50 of 249

Recommended Authors

Davide Bedognetti
College of Health and Life Sciences, Hamad Bin Khalifa University, Qatar Foundation
Career Start Year 2010
Number of shared co-authors 1
Anusha Kalbasi
Stanford Cancer Institute, Stanford School of Medicine
Career Start Year 2010
Number of shared co-authors 2
Harriet M Kluger
Yale School of Medicine
Career Start Year 2003
Number of shared co-authors 5
Hussein A Tawbi
MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 7
Mark E Smolkin
University of Virginia
Career Start Year 2002
Number of shared co-authors 2
Kimberly R Jordan
University of Colorado Anschutz Medical Campus
Career Start Year 2002
Number of shared co-authors 3
Bartosz Chmielowski
Jonsson Comprehensive Cancer Center, University of California Los Angeles
Career Start Year 1999
Number of shared co-authors 7
David J Liewehr
Center for Cancer Research
Career Start Year 1999
Number of shared co-authors 0
Cindy Sander
UPMC Hillman Cancer Center
Career Start Year 1997
Number of shared co-authors 4
Seunghee Kim-Schulze
Icahn School of Medicine at Mount Sinai
Career Start Year 1996
Number of shared co-authors 2
Zhiya Yu
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1995
Number of shared co-authors 0
Richard W Joseph
Mayo Clinic Hospital
Career Start Year 1994
Number of shared co-authors 5
Alan Melcher
The Institute of Cancer Research
Career Start Year 1994
Number of shared co-authors 1
Lawrence Fong
University of California san francisco
Career Start Year 1993
Number of shared co-authors 6
Marcus Bosenberg
Yale School of Medicine
Career Start Year 1992
Number of shared co-authors 10
Veena Kapoor
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1991
Number of shared co-authors 0
Suresh Nair
Lehigh Valley Topper Cancer Institute
Career Start Year 1990
Number of shared co-authors 3
Martin D McCarter
University of Colorado School of Medicine
Career Start Year 1989
Number of shared co-authors 3
Emile E Voest
The Netherlands Cancer Institute
Career Start Year 1989
Number of shared co-authors 2
Timothy M Kuzel
548377Rush University Medical Center
Career Start Year 1988
Number of shared co-authors 3
Jose A Lopez-Martin
Hospital Universitario 12 de Octubre
Career Start Year 1988
Number of shared co-authors 1
Craig L Slingluff
University of Virginia
Career Start Year 1987
Number of shared co-authors 5
Mary L Disis
University of Washington Medicine Cancer Vaccine Institute, University of Washington
Career Start Year 1986
Number of shared co-authors 7
Elizabeth M Jaffee
Convergence Institute, Johns Hopkins University
Career Start Year 1985
Number of shared co-authors 2
Nicholas P Restifo
National Cancer Institute, National Institutes of Health (NIH)
Career Start Year 1985
Number of shared co-authors 3
Seth M Steinberg
Center for Cancer Research, National Cancer Institute
Career Start Year 1984
Number of shared co-authors 1
Dave S B Hoon
Saint John's Cancer Institute at Saint John's Health Center
Career Start Year 1982
Number of shared co-authors 13
James M Reuben
The University of Texas MD Anderson Cancer Center
Career Start Year 1978
Number of shared co-authors 1
Peter J Selby
College of Agriculture and Life Sciences, Cornell University
Career Start Year 1977
Number of shared co-authors 1
Steven A Rosenberg
University of Colorado School of Medicine
Career Start Year 1961
Number of shared co-authors 8

Collaborators

Grant A McArthur
University of Melbourne
Co-authored papers 21
Georgina V Long
Co-authored papers 20
Lloyd J Old
Ludwig Institute for Cancer Research
Co-authored papers 19
Thomas John
Peter MacCallum Cancer Centre
Co-authored papers 12
Craig Gedye
Hunter Medical Research Institute, University of Newcastle
Co-authored papers 11
Otavia L Caballero
Ludwig Institute for Cancer Research Ltd.
Co-authored papers 10
Yao-Tseng Chen
From Population Health Services (Chen)
Co-authored papers 8
Damien Kee
Co-authored papers 8
John M Mariadason
Olivia Newton-John Cancer Research Institute
Co-authored papers 7
Aparna Jayachandran
The University of Queensland
Co-authored papers 7
Marzena Walkiewicz
Olivia Newton-John Cancer Research Institute
Co-authored papers 7
Rene Gonzalez
University of Colorado Anschutz Medical Campus
Co-authored papers 6
Richard A Scolyer
Co-authored papers 5
Antoni Ribas
University of California Los Angeles (university of california los angeles)
Co-authored papers 5
Paul Mitchell
Olivia Newton-John Cancer Research Institute
Co-authored papers 5
Reinhard Dummer
University Hospital Zurich
Co-authored papers 4
Siddhartha Deb
Olivia Newton-John Cancer Research Institute
Co-authored papers 4
Ulrich D??hrsen
University Hospital Essen, University of Duisburg-Essen
Co-authored papers 4
Caroline Robert
Co-authored papers 3
Nasser K Altorki
New York-Presbyterian Hospital
Co-authored papers 3
Dirk Schadendorf
Co-authored papers 3
Anthony T Papenfuss
Co-authored papers 3
Sacha Gnjatic
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Co-authored papers 3
John M Kirkwood
UPMC Hillman Cancer Center
Co-authored papers 3
Colin R Goding
Ludwig Institute for Cancer Research, University of Oxford
Co-authored papers 3
Anthony W Purcell
Monash Biomedicine Discovery Institute, Monash University
Co-authored papers 3
Peter J Dempsey
University of Colorado
Co-authored papers 3
Arun A Azad
Peter MacCallum Cancer Centre
Co-authored papers 3
Oliver Hofmann
University of Melbourne
Co-authored papers 3
Winston Hide
Harvard Medical School
Co-authored papers 3
Release 1.2